Financings Of The Fortnight: VCs Not Wowed By Single-Asset Company Model
This article was originally published in The Pink Sheet Daily
Venture capitalists tell START-UP’s annual survey that seeing will be believing when it comes to the potential of single-asset models. Plus news on recent financings by iPierian, Evotec, ObsEva and Acacia.
You may also be interested in...
VCs Back ObsEva With $35M For Trials On Pre-term Labor Drug
The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.
Prexton Therapeutics’ Parkinson’s Assets First to Emerge from Merck KGAA Restructuring
Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.